QIAGEN BEVERLY, INC. – Trademark Portfolio
Entity Type: 03
QIAGEN BEVERLY, INC. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 13 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 14 trademarks are registered. Notable registered marks include EXCELLA, FASTMIX, MYSTICQ, QSCRIPT, and REPLIQA. The owner is based in BEVERLY, MA.
100 CUMMINGS CENTER, SUITE 407J
BEVERLY, MA 01915
Showing of trademarks Trademarks
Trademark Classifications
QIAGEN BEVERLY, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does QIAGEN BEVERLY, INC. have?
QIAGEN BEVERLY, INC. has 15 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 cancelled.
What trademark classes does QIAGEN BEVERLY, INC. file in?
QIAGEN BEVERLY, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are QIAGEN BEVERLY, INC.'s most well-known trademarks?
QIAGEN BEVERLY, INC.'s registered trademark portfolio includes well-known marks such as EXCELLA, FASTMIX, MYSTICQ, QSCRIPT, and REPLIQA. These are among 14 currently registered trademarks in the portfolio.
What is QIAGEN BEVERLY, INC.'s trademark registration success rate?
QIAGEN BEVERLY, INC. has a 93% trademark registration rate, with 14 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.